ASPYRE simplifies and accelerates the detection of actionable biomarkers in both DNA and RNA from either tissue or plasma within two days to facilitate selection of the most effective targeted cancer treatments.
CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, May 25, 2023 (5:01pm EST) – Biofidelity, a revolutionary genomic technology company, announced that an abstract of data from its breakthrough ASPYRE® technology will be shared at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago, IL, USA.
The abstract: “Analytical performance assessment of ASPYRE-Lung: A new assay for rapid detection of actionable variants from tissue and plasma in NSCLC patients” is available in the ASCO meeting publication published today as abstract number e15038.
ASPYRE® technology enables rapid multi-gene testing in local laboratories using PCR instruments already present in laboratories around the world. Using ASPYRE’s unique molecular biology platform, Biofidelity has developed ASPYRE-Lung®, a rapid assay for identifying all NCCN guideline recommended biomarkers within two days of sample receipt with either plasma or tissue. Coupled with PDL-1 results, ASPYRE-Lung will identify the majority of actionable biomarkers for all newly diagnosed non-small cell lung cancer (NSCLC) patients.1
“ASPYRE makes genomic data more accessible and easier to interpret, helping to ensure that all patients, globally, have the information needed to receive the right treatment at the right time,” said Dr. Wendy Levin, Biofidelity’s Chief Medical Officer.
A published scientific paper describes the assay, including its ability to detect multiple gene fusions from RNA and to analyze DNA and RNA concurrently from a single patient sample. Direct fusion detection through RNA analysis is generally preferable compared to next generation sequencing based assays that detect abnormalities in DNA that are assumed to lead to pathogenic RNA fusions. According to the authors, detecting these fusions faster and at a lower cost has the potential to revolutionize patient care and make precision medicine globally accessible to more people.
Please join us at Biofidelity Booth #3088 at ASCO to learn more about ASPYRE or click here to set up a meeting to discuss ASPYRE-Lung.
Biofidelity is a revolutionary genomic technology company dedicated to making genomic analysis simpler, faster, and more efficient. Our novel molecular biology platform can be used on existing instrumentation in laboratories around the world to address applications across oncology by providing access to the vital information needed for accurate targeting and monitoring of cancer treatment. Our goal is to make genomic data far more accessible, at far lower cost, and bring the benefits of precision medicine to far more patients.
Founded in 2019, Biofidelity is a rapidly growing company of scientists, engineers, physicians and commercial experts dedicated to making genomics globally accessible.
For more information, please visit biofidelity.com and connect with us on LinkedIn and Twitter.
Biofidelity announces presentation of new data on novel genomic technology...
CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, October 28, 2022 – Biofidelity, a revolutionary genomic technology company, announced...
Biofidelity Announces Formation of Scientific Advisory Board
Cambridge, UK, 15 July 2021 – Biofidelity Ltd, the cancer diagnostics company, today announces the members of its newly-formed Scientific Advisory...